| Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery JD Tang, MN Mills, J Nakashima, AE Dohm, NI Khushalani, PA Forsyth, ... Journal of Neuro-Oncology 166 (3), 431-440, 2024 | 1 | 2024 |
| Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care I Smalley, A Boire, P Brastianos, HM Kluger, E Hernando‐Monge, ... Pigment Cell & Melanoma Research 37 (1), 51-67, 2024 | 2 | 2024 |
| Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease H Alhaddad, OE Ospina, ML Khaled, Y Ren, P Forsyth, Y Pina, ... bioRxiv, 2023 | | 2023 |
| HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis MF Emmons, RL Bennett, A Riva, K Gupta, LADC Carvalho, C Zhang, ... Nature communications 14 (1), 7759, 2023 | 2 | 2023 |
| RADT-07. CLINICAL OUTCOMES OF MELANOMA BRAIN METASTASES TREATED WITH NIVOLUMAB AND IPILIMUMAB ALONE VERSUS NIVOLUMAB AND IPILIMUMAB WITH STEREOTACTIC RADIOSURGERY J Tang, M Mills, A Dohm, N Khushalani, P Forsyth, MA Vogelbaum, ... Neuro-Oncology 25 (Supplement_5), v49-v49, 2023 | | 2023 |
| 351 Expansion of T cells from the cerebrospinal fluid of melanoma patients with leptomeningeal disease MI Carter, ML Hall, M Rodriguez-Valentin, M Beatty, P Forsyth, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Stereotactic radiosurgery and anti-PD-1+ CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the … AE Dohm, JY Nakashima, H Kalagotla, SX Jiang, JD Tang, M Bhandari, ... European Journal of Cancer 192, 113287, 2023 | 3 | 2023 |
| TIPS-04 A RANDOMIZED, MULTI-INSTITUTIONAL PILOT STUDY TO EVALUATE THE MOLECULAR AND CELLULAR RESPONSE TO TREATMENT WITH NIVOLUMAB WITH EITHER ADJUVANT IPILIMUMAB OR RELATLIMAB … Y Pina, A Chen, N Tran, A Etame, J Liu, AB Furlan, S Mokhtari, E Peguero, ... Neuro-Oncology Advances 5 (Supplement_3), iii34-iii34, 2023 | | 2023 |
| SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR … Y Pina, A Chen, J Arrington, R Macaulay, N Tran, J Liu, S Mokhtari, J Li, ... Neuro-Oncology Advances 5 (Supplement_3), iii28-iii28, 2023 | | 2023 |
| Factors improving overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review G Wallace, R Kundalia, B Cao, Y Kim, I Smalley, P Forsyth, A Soyano, ... Research Square, 2023 | 1 | 2023 |
| Phase 1B study of avelumab and whole brain radiotherapy (WBRT) in patients with leptomeningeal disease (LMD) from epithelial carcinomas: Final results and molecular analyses … Y Pina, A Chen, J Arrington, RJ Macaulay, ND Tran, JK Liu, S Mokhtari, ... Journal of Clinical Oncology 41 (16_suppl), 2598-2598, 2023 | | 2023 |
| Factors associated with overall survival in patients with melanoma leptomeningeal disease (M-LMD): A single institution retrospective review. K Nyman, R Kundalia, O Ospina, GC Wallace, Y Pina, I Smalley, ... Journal of Clinical Oncology 41 (16_suppl), e21548-e21548, 2023 | | 2023 |
| Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ … S Gandhi, PAJ Forsyth, M Opyrchal, KA Ahmed, K Attwood, EG Levine, ... Journal of Clinical Oncology 41 (16_suppl), TPS1112-TPS1112, 2023 | | 2023 |
| A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma YC Chen, M Jaffer, L Zhou, J Moslehi, PA Forsyth, LA Fecher American Society of Clinical Oncology Educational Book 43, e390594, 2023 | | 2023 |
| Defining the mechanisms of action and resistance to the anti-PD-1+ LAG-3 and anti-PD-1+ CTLA-4 combinations in melanoma flank and brain models MS Phadke, J Li, Z Chen, PC Rodriguez, JK Mandula, L Karapetyan, ... bioRxiv, 2023.04. 14.536907, 2023 | | 2023 |
| Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomeningeal lymphoma ML Khaled, G Wallace, B Evernden, Z Chen, H Alhaddad, Y Ren, ... Cancer Research 83 (7_Supplement), 1192-1192, 2023 | 1 | 2023 |
| Leptomeningeal disease (LMD) in patients with melanoma metastases ML Khaled, AA Tarhini, PA Forsyth, I Smalley, Y Piña Cancers 15 (6), 1884, 2023 | 7 | 2023 |
| Abstract PD7-06: Characteristics of Long-Term Survival in Breast Cancer Brain Metastasis after Stereotactic Radiation JD Tang, MN Mills, C Thawani, DE Oliver, A Soyano, A Etame, HHM Yu, ... Cancer Research 83 (5_Supplement), PD7-06-PD7-06, 2023 | | 2023 |
| Clinical outcomes of non–small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors … AE Dohm, JD Tang, MN Mills, CL Liveringhouse, ML Sandoval, BA Perez, ... Journal of Neurosurgery 138 (6), 1600-1607, 2022 | 7 | 2022 |
| RADT-11. CLINICAL OUTCOMES IN THE MANAGEMENT OF MELANOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY AND ANTI-PD-1+ CTLA-4 J Tang, A Dohm, H Kalagotla, M Bhandari, Y Kim, J Graham, ... Neuro-Oncology 24 (Supplement_7), vii51-vii51, 2022 | | 2022 |
